The FDA asked Johnson & Johnson (NYSE:JNJ) and a score of other medical device makers for data on metal levels in the blood of patients implanted with metal-on-metal hip implants.
Orthopedics
Welcome to MassDevice's Orthopedics Hub, your resource for the latest in orthopedic news. Stay informed about the innovations and business news shaping the ortho device industry.
🦴 Narrow your focus with these categories:
Implants | Metal-on-Metal | Spine
Here are the top orthopedic device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ The biggest stories from AAOS 2024
+ The 10 largest orthopedic device companies in the world
+ The ZimVie Tether helps kids with scoliosis — if they can get it in time
+ Could 2023 be a boom year for orthopedic devices?
+ The top orthopedic device news out of AAOS 2023
Latest Orthopedics News
Feds accuse Wright Medical of breaking deferred prosecution deal
A day after firing its top lawyer and two other executives, Wright Medical Group (NSDQ:WMGI) said the federal prosecutor for New Jersey accused it of breaking a deferred prosecution deal Wright struck last year to settle charges that it ran an illegal kickbacks scheme.
The Arlington, Tenn.-based orthopedic device maker also said it hired a new CEO, about a month after its surprise ouster of CEO Gary Henley and CTO Frank Bono.
Smith & Nephew not jealous over Synthes/JNJ union
Officials at Smith & Nephew (NYSE:SNN) weren’t acting brides left at the altar, but they weren’t exactly tossing bouquets to the hot new couple in the orthopedic market during a conference call with investors today.
Wright Medical shakeup continues with ouster of three more executives
Just a month after a surprise shakeup at Wright Medical Group saw CEO Gary Henley abruptly resign and CTO Frank Bono fired, the company replaced three more senior executives.
The Arlington, Tenn.-based maker of orthopedic devices for the foot and ankle market said in a regulatory filing that it had accepted the resignations of senior vice president, general counsel and secretary Raymond Kolls; vice president of clinical & regulatory affairs Alicia Napoli; and senior vice president for EMEA commercial operations Cary Hagan.
Johnson & Johnson CFO: Synthes deal doesn’t mean we’re done
Johnson & Johnson (NYSE:JNJ) may have just dropped a cool $21.3 billion to acquire Synthes (SWX:SYST.VX), but it doesn’t mean the health products giant is done shopping for deals.
“Although we just did a pretty significant deal, it doesn’t preclude us from doing another one,,” CFO Dominic Caruso told an investor’s conference in Boston. “We want to be able to act.”
InVivo and University of Miami team up on spinal injury research
InVivo Therapeutics Holdings Corp. signed a research deal with the University of Miami for collaboration on spinal cord injury treatments.
The Cambridge, Mass.-based company is developing a bio-compatible polymer scaffold for spinal injuries and plans to work with the Miami Project to Cure Paralysis at the university’s Miller School of Medicine, according to a filing with the Securities & Exchange Commission.
Zimmer’s hips swing in Q1
Zimmer Holdings Inc. (NYSE:ZMH) flexed its muscles in the hip business, riding strong sales in one of its key markets to a 5 percent jump in overall sales during the first quarter.
The Warsaw, Ind.-based orthopedic maker posted a $209 million profit on $1.11 billion in sales during the three months ended March 31, a 2 percent increase over the $205 million in net income on $1.06 billion in sales posted during the same period last year.
Synthes stays flat, Johnson and Johnson ticks down on $21 billion buyout
Orthopedic survey: Stryker, Zimmer the most innovative companies in hips and knees
DePuy hip recall: New Jersey benefits fund sues Johnson & Johnson
A fund that manages health benefits for 25 towns in northern New Jersey filed a class action lawsuit against Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics over its massive ASR hip implant recall.
In a civil suit filed in U.S. District Court for New Jersey late last week, the North Jersey Municipal Employee Benefits Fund accused J&J of fraud and unjust enrichment, alleging that the New Brunswick, NJ.-based medical conglomerate knew of problems with the implant but left it on the U.S. market anyway.
Synthes takeover could be the orthopedics makeover that Johnson & Johnson needs
MASSDEVICE ON CALL — Johnson & Johnson’s (NYSE:JNJ) may be looking at its proposed mega-merger with Synthes as a way to save its orthopedics business.